Earnings Summary

Esperion Therapeutics, Inc.’s revenue jumped 36.86% since last year same period to $25.79Mn in the Q2 2023. On a quarterly growth basis, Esperion Therapeutics, Inc. has generated 5.99% jump in its revenue since last 3-months.

Esperion Therapeutics, Inc.’s net profit jumped 24.71% since last year same period to $-49.94Mn in the Q2 2023. On a quarterly growth basis, Esperion Therapeutics, Inc. has generated 19.09% jump in its net profits since last 3-months.

Esperion Therapeutics, Inc.’s net profit margin jumped 44.99% since last year same period to -193.65% in the Q2 2023. On a quarterly growth basis, Esperion Therapeutics, Inc. has generated 23.66% jump in its net profit margins since last 3-months.

Esperion Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.84 - a 8.7% jump from last quarter’s estimates.

Esperion Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.84.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Esperion Therapeutics, Inc.’s return on assets (ROA) stands at -0.39.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Esperion Therapeutics, Inc.’s return on equity (ROE) stands at -2.61.